Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Decline in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 68,600 shares, a decrease of 33.9% from the January 31st total of 103,800 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average daily volume of 2,240,000 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 price target on shares of Senti Biosciences in a research report on Monday, December 2nd.

Senti Biosciences Stock Down 5.0 %

SNTI stock opened at $2.86 on Tuesday. The company has a 50 day moving average of $4.08 and a two-hundred day moving average of $3.37. Senti Biosciences has a 12-month low of $1.52 and a 12-month high of $16.94. The company has a market cap of $13.77 million, a price-to-earnings ratio of -0.18 and a beta of 2.46.

Institutional Trading of Senti Biosciences

A hedge fund recently bought a new stake in Senti Biosciences stock. Renaissance Technologies LLC bought a new position in Senti Biosciences, Inc. (NASDAQ:SNTI) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 51,600 shares of the company’s stock, valued at approximately $181,000. Renaissance Technologies LLC owned about 1.07% of Senti Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 25.73% of the company’s stock.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.